Could a vaccine made from your own cells help control HIV?

NCT ID NCT03758625

Completed Disease control Sponsor: Sharon Riddler Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested a therapeutic HIV vaccine made from each patient's own white blood cells. The goal was to see if it is safe and can boost the immune system to better control HIV. Forty adults on stable HIV treatment took part, receiving either a vaccine loaded with inactivated HIV or with conserved HIV peptides, or a control without antigen.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: autologous dendritic cells loaded with inactivated HIV or conserved HIV peptides
What this could lead to: If successful, this could point toward a way to help the immune system control HIV without needing daily medication.
What could go wrong: This is a very early phase 1 trial with only 40 people, so it may not work or may have side effects. It is not a cure and participants must stay on ART.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS

Contacts and locations

Locations

AIDS Clinical Trials Unit/The Ohio State University

Columbus, Ohio, 43210, United States
HIV/AIDS Clinical Research Unit / University of Pittsburgh

Pittsburgh, Pennsylvania, 15213, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.